Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY: NVS )

109.11 +0.47 (+0.43%)
Official Closing Price Updated: 7:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,638,111
Open 109.81
Bid (Size) 108.00 (1)
Ask (Size) 112.00 (1)
Prev. Close 108.64
Today's Range 108.87 - 110.11
52wk Range 92.35 - 120.92
Shares Outstanding N/A
Dividend Yield 3.46%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
These 2 Vanguard ETFs Are Crushing the S&P 500 in 2025. Should You Buy?
Via The Motley Fool
Topics ETFs Stocks
Exposures US Equities
Teladoc Health Partners With Eli Liily's LillyDirect to Expand Access to Zepbound For Weight Loss
Teladoc Health teams up with Eli Lilly's LillyDirect to improve Zepbound access, offering direct home delivery and comprehensive obesity care support. 
Via Benzinga

Performance

YTD
+12.32%
+12.32%
1 Month
+2.12%
+2.12%
3 Month
+10.02%
+10.02%
6 Month
-5.35%
-5.35%
1 Year
+9.36%
+9.36%

More News

Read More
Novartis Earns Near-Best Overall Rating As Profit Growth Climbs
Via Investor's Business Daily
NOVARTIS AG-SPONSORED ADR (NYSE:NVS) stands out as a stock that provides good value for the fundamentals it showcases.
Via Chartmill
Novartis Earnings Surprised The Street; Still Going Strong Despite Market Correction
Via Investor's Business Daily
Is the Market Bullish or Bearish on Novartis?
Via Benzinga
Roche Touts Food Allergy Drug As Superior Than Oral Immunotherapy
Via Benzinga
3 Dividend Stocks That Are No-Brainer Buys Right Now
Via The Motley Fool
Court Dismisses Novartis Challenge To Medicare Drug Price Negotiation Program
Via Benzinga
NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects
Via Benzinga
This Kraft Heinz Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday
Via Benzinga
Novartis To Beef Up Heart Disease Offering With $3 Billion Blackstone-Backed Anthos Therapeutics Deal
Via Benzinga
Super Bowl Commercials 2025: Complete List of Super Bowl LIX Ads And Companies Behind Them
Via Benzinga
Super Bowl LIX Commercials: AI, Celebs, Muppets, Warren Buffett-Linked Brand Take The Spotlight
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
2 High-Yield Dividend Stocks to Hold Through 2025 and Beyond
Via The Motley Fool
Novartis Ag (NVS) Q4 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Novartis Gets Retail Chatting After Upbeat Q4, But Sentiment Stays Tepid Amid Volatile Trading
Via Stocktwits
Topics Intellectual Property
Exposures Intellectual Property
Novartis Edges Higher On Sales Beat As Competition Looms For Its Biggest Moneymaker
Via Investor's Business Daily
Topics Earnings
Exposures Financial
US Stock Futures Climb After Apple Beats Q4 Expectations: Expert Says Tech Stocks Hold Above Key Level Despite DeepSeek Impact
Via Benzinga
Novartis Q4: Earnings Beat Estimates, CEO Dismisses Entresto Patent Expiration Worries
Via Benzinga
Topics Earnings Intellectual Property
Exposures Financial Intellectual Property
When you look at NYSE:NVS, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via Chartmill
Earnings Scheduled For January 31, 2025
Via Benzinga
AbbVie Vs. Novartis: Which Has The Technical Edge Before Q4 Earnings?
Via Benzinga
RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders
Via Benzinga
Topics Government
Exposures Political
AI Pharma: 2 Paths to AI-Powered Drug Investment
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.